| Casey Bishe, PT | |
|
227 S Pendleton St Ste B, Easley, SC 29640-3084 | |
| (864) 855-7030 | |
| (864) 855-7019 |
| Full Name | Casey Bishe |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 4 Years |
| Location | 227 S Pendleton St Ste B, Easley, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366052490 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 10218 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dosher Physical Therapy Associates Inc | 9931188836 | 9 |
News Archive
CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.
Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research.
› Verified 4 days ago
| Provider Name | Dosher Physical Therapy Associates Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1639163934 PECOS PAC ID: 9931188836 Enrollment ID: O20040715000158 |
News Archive
CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.
Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Casey Bishe, PT 227 S Pendleton St Ste B, Easley, SC 29640-3084 Ph: (864) 855-7030 | Casey Bishe, PT 227 S Pendleton St Ste B, Easley, SC 29640-3084 Ph: (864) 855-7030 |
News Archive
CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.
Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research.
› Verified 4 days ago
Excel Rehabilitation And Sports Enhancement Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1664 E Main St, Easley, SC 29640 Phone: 864-654-2001 | |
Julie K Shipe, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 706 Pelzer Hwy, Easley, SC 29642 Phone: 864-859-0167 Fax: 864-859-2312 | |
Willard Chandler White, DPT Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 838 Powdersville Rd Ste T, Easley, SC 29642 Phone: 864-671-1650 Fax: 864-442-2053 | |
Lori Bartenfeld, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 227 S. Pendleton Street, Ste B, Easley, SC 29640 Phone: 864-855-7030 Fax: 864-855-7019 | |
Brady Pediatric Therapy Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 350 Hamilton Pkwy, Easley, SC 29642 Phone: 217-713-8333 | |
Physical Therapy Consultants Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 115 Brushy Creek Rd, Easley, SC 29642 Phone: 864-343-2650 | |
Mary Ann Ketterman, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 227 S Pendleton St, Suite B, Easley, SC 29640 Phone: 864-855-7030 Fax: 864-855-7019 |